122 related articles for article (PubMed ID: 37542453)
21. A dual catalytic functionalized hollow mesoporous silica-based nanocarrier coated with bacteria-derived exopolysaccharides for targeted delivery of irinotecan to colorectal cancer cells.
Fatemi M; Meshkini A; Matin MM
Int J Biol Macromol; 2024 Feb; 259(Pt 1):129179. PubMed ID: 38181911
[TBL] [Abstract][Full Text] [Related]
22. In situ biodegradable crosslinking of cationic oligomer coating on mesoporous silica nanoparticles for drug delivery.
Wang Y; Wang J; Yang Y; Sun Y; Yuan Y; Li Y; Liu C
Colloids Surf B Biointerfaces; 2017 May; 153():272-279. PubMed ID: 28279933
[TBL] [Abstract][Full Text] [Related]
23. Mesoporous silica@chitosan@gold nanoparticles as "on/off" optical biosensor and pH-sensitive theranostic platform against cancer.
Esmaeili Y; Khavani M; Bigham A; Sanati A; Bidram E; Shariati L; Zarrabi A; Jolfaie NA; Rafienia M
Int J Biol Macromol; 2022 Mar; 202():241-255. PubMed ID: 35041881
[TBL] [Abstract][Full Text] [Related]
24. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
25. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
26. Sugar-conjugated dendritic mesoporous silica nanoparticles as pH-responsive nanocarriers for tumor targeting and controlled release of deferasirox.
Sodagar Taleghani A; Ebrahimnejad P; Heidarinasab A; Akbarzadeh A
Mater Sci Eng C Mater Biol Appl; 2019 May; 98():358-368. PubMed ID: 30813037
[TBL] [Abstract][Full Text] [Related]
27. Multistage pH-responsive mesoporous silica nanohybrids with charge reversal and intracellular release for efficient anticancer drug delivery.
Yuan X; Peng S; Lin W; Wang J; Zhang L
J Colloid Interface Sci; 2019 Nov; 555():82-93. PubMed ID: 31377647
[TBL] [Abstract][Full Text] [Related]
28. Biodegradable hybrid mesoporous silica nanoparticles for gene/chemo-synergetic therapy of breast cancer.
Zhang B; Liu Q; Liu M; Shi P; Zhu L; Zhang L; Li R
J Biomater Appl; 2019 May; 33(10):1382-1393. PubMed ID: 30880565
[TBL] [Abstract][Full Text] [Related]
29. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin loaded large-pore mesoporous hydroxyapatite coated superparamagnetic Fe3O4 nanoparticles for cancer treatment.
Abbasi Aval N; Pirayesh Islamian J; Hatamian M; Arabfirouzjaei M; Javadpour J; Rashidi MR
Int J Pharm; 2016 Jul; 509(1-2):159-167. PubMed ID: 27234695
[TBL] [Abstract][Full Text] [Related]
31. Albumin-MnO
Fang J; Wang Q; Yang G; Xiao X; Li L; Yu T
Colloids Surf B Biointerfaces; 2019 Jul; 179():250-259. PubMed ID: 30978612
[TBL] [Abstract][Full Text] [Related]
32. pH-responsive poly (acrylic acid)-gated mesoporous silica and its application in oral colon targeted drug delivery for doxorubicin.
Tian B; Liu S; Wu S; Lu W; Wang D; Jin L; Hu B; Li K; Wang Z; Quan Z
Colloids Surf B Biointerfaces; 2017 Jun; 154():287-296. PubMed ID: 28351801
[TBL] [Abstract][Full Text] [Related]
33. Enhanced anti-tumor activity of a drug through pH-triggered release and dual targeting by calcium phosphate-covered mesoporous silica vehicles.
Liu J; Hu X; Jin S; Liang XJ; Ma X
J Mater Chem B; 2022 Jan; 10(3):384-395. PubMed ID: 34935843
[TBL] [Abstract][Full Text] [Related]
34. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
Zhang Q; Zhao H; Li D; Liu L; Du S
Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
[TBL] [Abstract][Full Text] [Related]
35. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
Li Z; Zhang L; Tang C; Yin C
Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
[TBL] [Abstract][Full Text] [Related]
36. Magneto-Fluorescent Mesoporous Nanocarriers for the Dual-Delivery of Ofloxacin and Doxorubicin to Tackle Opportunistic Bacterial Infections in Colorectal Cancer.
Marcelo GA; Galhano J; Robalo TT; Cruz MM; Marcos MD; Martínez-Máñez R; Duarte MP; Capelo-Martínez JL; Lodeiro C; Oliveira E
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293142
[TBL] [Abstract][Full Text] [Related]
37. A controlled-release nanocarrier with extracellular pH value driven tumor targeting and translocation for drug delivery.
Zhao Z; Meng H; Wang N; Donovan MJ; Fu T; You M; Chen Z; Zhang X; Tan W
Angew Chem Int Ed Engl; 2013 Jul; 52(29):7487-91. PubMed ID: 23757374
[TBL] [Abstract][Full Text] [Related]
38. Esterase- and pH-responsive poly(β-amino ester)-capped mesoporous silica nanoparticles for drug delivery.
Fernando IR; Ferris DP; Frasconi M; Malin D; Strekalova E; Yilmaz MD; Ambrogio MW; Algaradah MM; Hong MP; Chen X; Nassar MS; Botros YY; Cryns VL; Stoddart JF
Nanoscale; 2015 Apr; 7(16):7178-83. PubMed ID: 25820516
[TBL] [Abstract][Full Text] [Related]
39. A Sequentially Responsive Nanosystem Breaches Cascaded Bio-barriers and Suppresses P-Glycoprotein Function for Reversing Cancer Drug Resistance.
Liu J; Zhao L; Shi L; Yuan Y; Fu D; Ye Z; Li Q; Deng Y; Liu X; Lv Q; Cheng Y; Xu Y; Jiang X; Wang G; Wang L; Wang Z
ACS Appl Mater Interfaces; 2020 Dec; 12(49):54343-54355. PubMed ID: 32959645
[TBL] [Abstract][Full Text] [Related]
40. Increased Toxicity of Doxorubicin Encapsulated into pH-Responsive Poly(β-Amino Ester)-Functionalized MCM-41 Silica Nanoparticles.
Ávila-Ortega A; Carrillo-Cocom LM; Olán-Noverola CE; Nic-Can GI; Vilchis-Nestor AR; Talavera-Pech WA
Curr Drug Deliv; 2020; 17(9):799-805. PubMed ID: 32723272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
